Organization | Nivagen Pharmaceuticals Inc.

Nivagen Pharmaceuticals Inc. Report issue

For profit Phase 2

Founded: Sacramento CA United States (2009)

Status: No NME R&D (2009)

Organization Overview

First Clinical Trial

2018

NCT03335774

First Marketed Drug

2009

nystatin (mycostatin)

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Nivagen Pharmaceuticals Inc. | NIVAGEN PHARMS INC

Active Ingredients

Marketed Drugs (9)

calcium citrate (2022)

decitabine (dacogen) (2020)

efinaconazole (jublia) (2021)

glycopyrronium (robinul) (2021)

l-cysteine (cysteine hydrochloride) (2023)

neostigmine (bloxiverz) (2022)

nystatin (mycostatin) (1991)

succinylcholine (anectine) (2020)

temozolomide (temodar) (2021)

Drugs in Phase 2 Trials (1)

hydrocortisone (solu-cortef) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hemorrhoids (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 1
# of Trial APIs: 1